

University of Nebraska Medical Center DigitalCommons@UNMC

Journal Articles: Epidemiology

Epidemiology

2012

Antibiotics for Leptospirosis

David Brett-Major

Rodney Coldren

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles

Part of the Epidemiology Commons



Cochrane Database of Systematic Reviews

Antibiotics for leptospirosis (Review)

Brett-Major DM, Coldren R

Brett-Major DM, Coldren R. Antibiotics for leptospirosis. *Cochrane Database of Systematic Reviews* 2012, Issue 2. Art. No.: CD008264. DOI: 10.1002/14651858.CD008264.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

HEADER 1
ABSTRACT 1
PLAIN LANGUAGE SUMMARY
BACKGROUND
OBJECTIVES
METHODS
RESULTS
Figure 1
Figure 2
Figure 3
DISCUSSION
AUTHORS' CONCLUSIONS
ACKNOWLEDGEMENTS
REFERENCES
CHARACTERISTICS OF STUDIES
DATA AND ANALYSES
Analysis 1.1. Comparison 1 Antibiotics versus placebo, Outcome 1 Death
Analysis 1.2. Comparison 1 Antibiotics versus placebo, Outcome 2 Days of hospitalisation
Analysis 1.3. Comparison 1 Antibiotics versus placebo, Outcome 3 Days of clinical illness
Analysis 1.4. Comparison 1 Antibiotics versus placebo, Outcome 4 Dialysis employed
Analysis 1.5. Comparison 1 Antibiotics versus placebo, Outcome 5 Days of fever
Analysis 2.1. Comparison 2 Cephalosporin versus penicillin, Outcome 1 Death
Analysis 2.2. Comparison 2 Cephalosporin versus penicillin, Outcome 2 Days of fever
Analysis 3.1. Comparison 3 Doxycycline versus penicillin, Outcome 1 Death
Analysis 3.2. Comparison 3 Doxycycline versus penicillin, Outcome 2 Days of fever
Analysis 4.1. Comparison 4 Azithromycin versus doxycycline, Outcome 1 Afebrile within 48 hours of initiation of therapy 24
Analysis 5.1. Comparison 5 Cephalosporin versus doxycycline, Outcome 1 Death
APPENDICES
CONTRIBUTIONS OF AUTHORS
DECLARATIONS OF INTEREST
DIFFERENCES BETWEEN PROTOCOL AND REVIEW
NOTES
INDEX TERMS

[Intervention Review]

Antibiotics for leptospirosis

David M Brett-Major¹, Rodney Coldren²

¹U.S. Military Tropical Medicine, Navy Medicine Manpower, Personnel, Training and Education Command (NAVMED MPT&E), Bethesda, MD, USA. ²Department of Preventive Medicine and Biometrics, Uniformed Services University, Bethesda, USA

Contact address: David M Brett-Major, U.S. Military Tropical Medicine, Navy Medicine Manpower, Personnel, Training and Education Command (NAVMED MPT&E), 8901 Wisconsin Avenue, Bethesda, MD, 20889-5611, USA. dmbrettmajor@gmail.com, David.Brett-Major@med.navy.mil.

Editorial group: Cochrane Hepato-Biliary Group. **Publication status and date:** New, published in Issue 2, 2012.

Citation: Brett-Major DM, Coldren R. Antibiotics for leptospirosis. *Cochrane Database of Systematic Reviews* 2012, Issue 2. Art. No.: CD008264. DOI: 10.1002/14651858.CD008264.pub2.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Leptospirosis has a wide-ranging clinical and public health impact. *Leptospira* are globally distributed. Case attack rates are as high as 1:4 to 2:5 persons in exposed populations. In some settings mortality has exceeded 10% of infected people. The benefit of antibiotic therapy in the disease has been unclear.

Objectives

We sought to characterise the risks and benefits associated with use of antibiotic therapy in the management of leptospirosis.

Search methods

We searched the The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library*, MEDLINE, EMBASE, and Science Citation Index Expanded regardless of study language. This was augmented by a manual search. The last date of search was November, 2011.

Selection criteria

To be included in assessment of benefits, trials had to specifically assess the use of antibiotics in a randomised clinical trial. A broad range of study types were incorporated to seek potential harms.

Data collection and analysis

Included trials were systematically abstracted, as were excluded studies for the purposes of assessing harms. Analyses were conducted in accordance with The Cochrane Handbook and practices of The Cochrane Hepato-Biliary Group.

Main results

Seven randomised trials were included. Four trials with 403 patients compared an antibiotic with placebo or no intervention. Three trials compared at least one antibiotic regimen with another antibiotic regimen. The trials all had high risk of bias. The trials varied in the severity of leptospirosis among trial patients. The ability to group data for meta-analysis was limited. While all four trials that compared antibiotics with placebo reported mortality and used parenteral penicillin, there were no deaths in two of them. Since odds ratio calculations cannot employ zero-event trials, only two trials contributed to this estimate. The number of deaths were 16/200 (8.0%) in the antibiotic arm versus 11/203 (5.4%) in the placebo arm giving a fixed-effect OR 1.56 (95% CI 0.70 to 3.46). The random-effects OR is 1.16 (95% CI 0.23 to 5.95). The heterogeneity among these four trials for the mortality outcome was moderate (I²= 50%). Only one trial (253 patients) reported days of hospitalisation. It compared parenteral penicillin to placebo without significant effect of therapy (8.9 versus 8.8 days; mean difference (MD) 0.10 days, 95% CI -0.83 to 1.03). The difference in days of clinical illness was reported in two of these trials (71 patients). While parenteral



penicillin therapy conferred 4.7 to 5.6 days of clinical illness in contrast to 7.7 to 11.6 days in the placebo arm, the size of the estimate of effect increased but statistical significance was lost under the random-effect model (fixed-effect: MD -2.13 days, 95% CI -2.46 to -1.80; random-effects: MD -4.04, 95% CI -8.66 to 0.58). I² for this outcome was high (81%). When duration of fever alone was assessed between antibiotics and placebo in a single trial (79 patients), no significant difference existed (6.9 versus 6.6 days; MD 0.30, 95% CI -1.26 to 1.86). Two trials with 332 patients in relatively severe and possibly late leptospirosis, resulted in trends towards increased dialysis when penicillin was used rather than placebo, but the estimate of effect was small and did not reach statistical significance (42/163 (25.8%) versus 31/169 (18.4%); OR 1.54, 95% CI 0.91 to 2.60). When one antibiotic was assessed against another antibiotic, there were no statistically significant results. For mortality in particular, these comparisons included cephalosporin versus penicillin (2 trials, 6/176 (3.4%) versus 9/175 (5.2%); fixed-effect: OR 0.65, 95% CI 0.23 to 1.87, I²= 16%), doxycycline versus penicillin (1 trial, 2/81 (2.5%) versus 4/89 (4.5); OR 0.54, 95% CI 0.10 to 3.02), cephalosporin versus doxycycline (1 trial, 1/88 (1.1%) versus 2/81 (2.5%); OR 0.45, 95% CI 0.04 to 5.10). There were no adverse events of therapy which reached statistical significance.

Authors' conclusions

Insufficient evidence is available to advocate for or against the use of antibiotics in the therapy for leptospirosis. Among survivors who were hospitalised for leptospirosis, use of antibiotics for leptospirosis may have decreased the duration of clinical illness by two to four days, though this result was not statistically significant. When electing to treat with an antibiotic, selection of penicillin, doxycycline, or cephalosporin does not seem to impact mortality nor duration of fever. The benefit of antibiotic therapy in the treatment of leptospirosis remains unclear, particularly for severe disease. Further clinical research is needed to include broader panels of therapy tested against placebo.

PLAIN LANGUAGE SUMMARY

Antibiotics for the treatment of leptospirosis

Leptospirosis is a common disease both in the developed and developing world. It is caused by a bacteria spread by the urine of animals. People travelling, agricultural field workers, hunters, homeless, and others with close animal contact are groups that, in particular, can get leptospirosis. Like many common infections, most people infected with this disease do not feel sick. When people do feel sick, in some instances up to 1 out of every 10 people have died. Whether or not antibiotics should be used, and if used which antibiotic should be used have been matters for debate for many years. This review identified and assessed seven clinical trials that tested antibiotics in patients sick with leptospirosis. Four of these trials compared intravenous penicillin to a placebo. Three of the trials looked at differences between different antibiotics. All trials had high risk of systematic errors (bias) and of random errors (play of chance). When looked at together, these trials do not answer the basic questions about whether or not antibiotics should be used. Part of the reason for this is that there is a wide range of severity among people ill with the disease. Additional randomised clinical trials are needed. Nonetheless, these trials suggest that antibiotics administered to patients who are sick with leptospirosis may make patients feel better two days earlier than they otherwise would have improved. However, it is also possible that when patients are severely ill, penicillin therapy might increase the risk of death or dialysis in comparison to those who receive no antibiotics. Other antibiotics have not been tested in this way. Despite the lack of evidence, if a clinician chooses to treat leptospirosis with an antibiotic, there does not seem to be any difference between the appropriate use of intravenous penicillin, intravenous cephalosporin, doxycyline, or azithromycin. But, for this they have not been tested to the same extent as intravenous penicillin.



BACKGROUND

Leptospira species have a wide geographic distribution in nature and are recognised as causing zoonotic clinical disease (leptospirosis) predominantly in the Americas, Carribean, and Asia (Pappas 2008). While World Health Organization (WHO) guidelines admit that both morbidity and mortality in leptospirosis are variably determined, the guidelines strongly promote the use of targeted antibiotic therapy as soon as leptospirosis is considered a leading element of the differential diagnosis in an ill patient (WHO 2003). This is despite recognition that benefits of therapy historically have been unclear (Bharti 2003). Point of care diagnosis for leptospirosis is not in use. While clinical scoring exists, serologic assays, ideally with acute and convalescent sera and culture employing specialised media, are required.

Deaths occur in outbreaks most commonly from renal failure and pulmonary haemorrhage. Proportions of symptomatic disease among exposed persons have ranged from 26% to 40% in small studies among immune naive populations (Russell 2003; Sejvar 2003; Hadad 2006). Mortality among symptomatic patients also may be high. After the 2005 flooding in Guyana, one group reported six deaths among 40 clinical presentations to a referral centre (Liverpool 2008).

We sought to better define the role of antibiotic therapy in patients with leptospirosis and update a previously published Cochrane systematic review (Guidugli 2000). That review pooled three trials and demonstrated no statistically significant benefit for either mortality or number of days hospitalised when doxycycline and penicillin were compared with placebo.

OBJECTIVES

To assess the beneficial and harmful effects of antibiotics for the treatment of leptospirosis.

METHODS

Criteria for considering studies for this review

Types of studies

We considered for inclusion all randomised clinical trials studying antibiotics for the treatment of leptospirosis regardless of year, language, form of publication, blinding, or comparator (Higgins 2011). In order to assess potential harm, we searched for contributory cohort studies, case-control studies, and quasirandomised studies.

Types of participants

All infected patients were included, though we anticipated that most participants would be victims of seasonal flooding, agricultural workers in endemic regions, veterinarians, and other high-risk occupations as well as high-risk activity travellers, such as troops and eco-tourists, potentially exposed to *Leptospira* infection.

Types of interventions

Administration of antibiotic expressly given for the treatment of leptospirosis versus placebo, no intervention, or another antibiotic.

We did not exclude studies based upon type of antibiotic, dose, dose interval, route of administration, or timing of dose, though these factors were relevant for pooling. We allowed cointerventions when equally administered to all trial groups.

Types of outcome measures

We evaluated selected trials for the following outcome measures:

Primary outcomes

- Overall mortality.
- · Leptospirosis mortality (confirmed by laboratory diagnosis).
- Hospitalisation (regardless of cause).
- Leptospirosis hospitalisation (confirmed by laboratory diagnosis).
- Among those with hospitalisation for leptospirosis confirmed by laboratory diagnosis, ventilator requirement.
- Among those with hospitalisation for leptospirosis confirmed by laboratory diagnosis, dialysis requirement.

Secondary outcomes

- Days lost from work or travel.
- Among those with hospitalisation for leptospirosis confirmed by laboratory diagnosis and ventilated, number of days on mechanical ventilation.
- Among those with hospitalisation for leptospirosis confirmed by laboratory diagnosis and dialyzed, number of days on dialysis.
- Adherence to assigned intervention.
- All adverse events. An adverse event defined as any untoward medical occurrence in a patient in any trial group, regardless of association with the intervention, but that results in a dose reduction, discontinuation of treatment, or registration as an adverse event (ICH-GCP 1996). We characterised events into the following strata:
 - * Minor not requiring intervention.
 - * Minor requiring intervention.
 - Requiring hospitalisation or resulting in long-term disability.
 - * Death (ICH-E3 1995).

Search methods for identification of studies

We performed electronic and manual searches.

Electronic searches

We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (Gluud 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library*, MEDLINE, EMBASE, and Science Citation Index Expanded (Royle 2003). Search strategies with the time span of the searches are given in Appendix 1. Once we selected a trial for inclusion, we used its bibliography to search for candidate trials. In MEDLINE, we used the 'Related links' feature to search the 25 most related publications to each selected study.

Searching other resources

We attempted contact with the authors of included trials in press within the previous 20 years. We provided a draft of this review in order to afford them an opportunity to supplement study information to better inform study description or incorporated data. Such correspondences were sent on 15 May 2011.

Data collection and analysis

ochrane

We followed the instructions in The *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) and the Cochrane Hepato-Biliary Group Module (Gluud 2011) for data collection and analysis.

Selection of studies

Both authors independently reviewed the entire list of candidate studies obtained by databases search for compliance with the selection requirements. The authors did not have disagreement on inclusion of individual trials; however, they, if necessary, had available arbitration through The Cochrane Hepato-Biliary Group Editorial Team Office.

Data extraction and management

We abstracted each selected study with two independent abstractions.

As available, we extracted the following information from each selected study:

- Study and publication identifiers
 - Database index number, first author, journal, year of publication, and language.
 - Location, period of intervention, duration participants were followed.
 - Funding source.
- Study design
 - Inclusion and exclusion criteria.
 - Sample size (premise, calculation).
 - Outcome measures.
 - Randomisation and how randomised participants were allocated across groups.
 - Definitions of outcomes, in particular clinical and laboratory diagnosis.
 - Assigned interventions and control.
 - Who was blinded and how concealment was accomplished.
 - Dichotomous: If not selected for inclusion for analysis of benefit, should it be abstracted to inform analysis of harms? (if yes, abstract).
 - Dichotomous: If not selected for inclusion for analysis of benefit, should it be abstracted to inform the discussion? (if yes, abstract).
- Participant demographics
 - Age.
 - Sex.
 - Nature of exposure (agricultural worker, eco-tourist, etc).
- Results
 - Observed outcomes as published and augmented by author query.
 - Follow-up.
 - Completion rates by trial arms.
 - Type of analysis (intention-to-treat sought).

Assessment of risk of bias in included studies

We followed the instructions given in the *Cochrane Handbook* for *Systematic Reviews of Interventions* (Higgins 2011) and the Cochrane Hepato-Biliary Group Module (Gluud 2011). Due to the risk of biased overestimation of intervention effects in randomised trials with inadequate methodological quality (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008), we looked at the influence of methodological quality of the trials on the results by evaluating the risk of bias domains described below. When information was not available in the published trial, we contacted the authors in an attempt to assess each trial fully. Explicit methodologic grading criteria are recommended standard in the Cochrane Hepato-Biliary Group Module (Gluud 2011).

Allocation sequence generation

- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent adjudicator.

- Uncertain risk of bias: the trial is described as randomised, but the method of sequence generation was not specified.

- High risk of bias: the sequence generation method is not, or may not be, random. Quasi-randomised studies, those using dates, names, or admittance numbers in order to allocate patients are inadequate and will be excluded for the assessment of benefits but not for harms.

Allocation concealment

Low risk of bias: allocation was controlled by a central and independent randomisation unit, sequentially numbered, opaque and sealed envelopes or similar, so that intervention allocations could not have been foreseen in advance of, or during, enrolment.
Uncertain risk of bias: the trial was described as randomised, but the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.

- High risk of bias: if the allocation sequence was known to the investigators who assigned participants, or if the study was quasi-randomised. Quasi-randomised studies will be excluded for the assessment of benefits but not for harms.

Blinding

- Low risk of bias: the trial was described as blinded, the parties that were blinded, and the method of blinding was described so that knowledge of allocation was adequately prevented during the trial.
- Uncertain risk of bias: the trial was described as blinded, but the method of blinding was not described so that knowledge of allocation was possible during the trial.

- High risk of bias, the trial was not blinded so that the allocation was known during the trial.

Incomplete outcome data

- Low risk of bias: the numbers and reasons for dropouts and withdrawals in all intervention groups were described, or if it was specified that there were no dropouts or withdrawals.

- Uncertain risk of bias: the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.

- High risk of bias: the number or reasons for dropouts and withdrawals were not described.

Selective outcome reporting

Antibiotics for leptospirosis (Review)

- Low risk of bias: death and dialysis are reported on.

- Uncertain risk of bias: either death or dialysis is not reported on, or are not reported fully, or it is unclear whether data on these outcomes were recorded or not.

- High risk of bias: either death or dialysis is not reported on; data on these outcomes were likely to have been recorded.

Other bias

While each study was assessed qualitatively for unexpected sources of bias, each trial was assessed in particular for funding and academic biases.

- Low risk of bias: the trial appears to be free of other components that could put it at risk of bias. Funding - sources clearly delineated and non-commercial; Academic - searchable literature from the study group which demonstrated balanced conclusions on the topic of publication.

- Uncertain risk of bias: the trial may or may not be free of other components that could put it at risk of bias. Funding - not disclosed or incomplete; Academic - not discernible due to lack of searchable literature.

- High risk of bias: there are other factors in the trial that could put it at risk of bias, eg, for-profit involvement, authors have conducted trials on the same topic etc. Funding - commercial sponsors particularly if lacking statement on level of participation in study execution by sponsors; Academic - searchable literature from the study group which demonstrated persistently themed conclusions on the topic of publication.

We abstracted selected studies independently of each other and without masking of the trial names. Mediation was not necessary. We used an abstraction form detailing information for global bias risk assessment and potential subgroup analyses.

We assessed selection and observation biases by abstracting core trial methodologies to include inclusion and exclusion criteria, randomisation, blinding, outcome definitions, and follow-up. We used each trial's enrolling definitions, duration of participant following, and surveillance methods in order to assess lead and lagtime biases.

Trials assessed as having 'low risk of bias' in all individual domains were considered 'trials with low risk of bias'. Trials assessed as having 'uncertain risk of bias' or 'high risk of bias' in one or more of the specified individual domains were considered trials with 'high risk of bias'.

Dealing with missing data

Analyses were planned for the primary categorical outcome measures with five potential scenarios to the intention-to-treat analyses as able from the available published and author supplemented data (Hollis 1999). These scenarios are described in the Cochrane Hepato-Biliary Group Module (Gluud 2011) and are defined as the following:

- Carry-forward analysis: for all participants with missing data, regardless of group, the last reported observed response will be used.
- Poor outcome analysis: assumes that all of the participants with missing data (from either group) had the outcome of interest.

- Good outcome analysis: assumes that none of the participants with missing data (from either group) had the outcome of interest.
- Extreme-case favouring antibiotic therapy: assumes that none of the participants with missing data from the antibiotic group had the outcome of interest, whereas all of those from the control group had the outcome of interest.
- Extreme-case favouring control: assumes that all of the participants with missing data from the antibiotic group had the outcome of interest, whereas none from the control group had the outcome of interest.

Assessment of heterogeneity

Heterogeneity was assessed using the Chi-square test and I-square statistic.

Data synthesis

We attempted to assess each outcome on an intention-to-treat basis, though some trials failed to report the necessary data for this. Trial context and methods were assessed to determine if pooling of their data was appropriate.

We used Cochrane's Review Manager 5.1 software (RevMan 2011) to calculate individual trial estimates where appropriate generate meta-analyses of trials' estimates of effect as well as to perform stability analysis when indicated. When pooling of data was appropriate, we performed both fixed-effect and random-effects modelling. We reported the fixed-effect result when there was no difference between them. Otherwise, we reported both results. Trials that assessed an antibiotic against placebo were analysed separately from trials that assessed one antibiotic regimen with another one.

Subgroup analysis and investigation of heterogeneity

Two subgroup categorisations appeared relevant after initial evaluation of included trials: severe versus not-severe leptospirosis and troops or travellers versus endemic populations. However, these subgroups when sufficiently distinguishable did not overlap substantively providing data (events) to inform trial objectives.

Where considerable heterogeneity was present ($l^2 > 50\%$), we evaluated trial differences such as patient population and trial definitions.

Sensitivity analysis

We performed sensitivity analyses for pre-defined outcomes when sufficient applicable trials were available.

Pre-planned analyses were (but ultimately not relevant in this review because of a lack of overlap of outcomes for analysis and subgroup):

- Trials with low risk of bias compared to trials with high risk of bias.
- By presence of adequate methodological components compared with unclear or inadequate components.
- By presence or absence of blinding.
- By presentation forum (abstracts versus peer-reviewed journal).
- By specificity of inclusion criteria.

Copyright $\ensuremath{\mathbb G}$ 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



- Iterative removal of trials from the meta-analysis to isolate sources of heterogeneity.
- Given sufficient number of selected trials (more than 10), we planned to perform funnel plot asymmetry analysis of trial size against antibiotic treatment in order to assess small-trial effects suggesting bias (Egger 1997).

RESULTS


Description of studies

Results of the search

Record yields from each of the components of the search strategy and subsequent vetting of results is delineated in Figure 1.



Figure 1. Study flow diagram.





Included studies

Seven trials met inclusion criteria and were incorporated (Characteristics of included studies). Four of these were from the last decade and three from the 1980s. One of the trials evaluated troops in a training area while the others assessed interventions in resident populations.

Excluded studies

Five studies were excluded. Their details are provided (Characteristics of excluded studies). Reasons for exclusion ranged from use of retrospective data and mixed infections to no disclosure of definition for a patient's disease. Four of the five excluded studies

were from the 1950s. Two studies provided information relevant to adverse events of therapy. Their contributions are discussed in that section.

Risk of bias in included studies

A determination of unclear bias was more common in older rather than newer trials. The presence of sufficient evidence to identify high risk of bias was present most frequently related to blinding. Specific comments on risk of bias are provided (Characteristics of included studies), as is a summary of study performance with regards to bias (Figure 2; Figure 3). Each of the seven included trials were at unclear or high risk for at least one bias domain and thus they fell into the group of trials with high risk of bias.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.







Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



One trial excluded three patients for problems obtaining post discharge following (Suputtamongkol 2004), one patient in the cefotaxime group and two in the penicillin group. Data for death are given in the text under both the poor outcome scenario (which also is the extreme case scenario favouring doxycycline against penicillin and cefotaxime) and good outcome scenario (which also is the extreme case scenario favouring penicillin and cefotaxime against doxycycline). Data in the figures and tables reflect the poor outcome scenario. They were not considered for other outcomes. Carry forward analysis was not relevant to this situation.

Allocation

Generation of allocation sequence was described adequately in five trials and allocation concealment adequately in four out of the seven included trials.

Blinding

All seven included trials were either at high or unclear risk for bias related to blinding. Blinding methodology either was not reported or not performed across trials.



Incomplete outcome data

Attrition was well delineated or minimised in three of the seven trials. In the single trial assessing azithromycin versus doxycycline for the treatment of leptospirosis, nearly a third of randomised patients were either not able to be assessed for post-discharge outcome or unable to be categorised as having leptospirosis or scrub typhus, or neither due to lack of suitable convalescent sera (Phimda 2007). Carry-forward analysis was not employed, however, the other four scenarios for dealing with missing data are represented with their relevant results.

Selective reporting

Two out of seven of the trials robustly reported on relevant outcomes (Costa 2003; Panaphut 2003) while in the other trials it was less clear but possible that all intended observations were reported.

Other potential sources of bias

Only one trial was demonstrably free of academic and funding biases (Costa 2003).

Effects of interventions

Five main comparator groups existed among included trials: antibiotics compared with placebo; cephalosporin compared with penicillin; doxycycline compared with penicillin; azithromycin compared with doxycycline; cephalosporin compared with doxycycline. Inclusion criteria for these trials required laboratory confirmation of leptospirosis, though the laboratory definition varied. Low number of outcomes and qualitative vice quantitative description of ventilator and dialysis requirements prevented assessment of the impact of therapy on these primary outcomes. None of the trials assessed attempted to intervene on hospitalisation through antimicrobial therapy.

Antibiotics versus placebo

While all four trials that compared antibiotics with placebo did report mortality (McClain 1984; Edwards 1988; Watt 1988; Costa 2003), there were no deaths in two of them (McClain 1984; Watt 1988). Since odds ratio calculations cannot employ zero-event trials, only two trials contributed to this estimate (Edwards 1988; Costa 2003). The calculated fixed-effect OR (1.56, 95% CI 0.70 to 3.46) (Analysis 1.1), while not achieving statistical significance, is in the direction that favours placebo (skewed rightward). However, the estimate is driven by the larger trial (Costa 2003), and the directions of effect in the two trials are opposite. Consistent with this, the random-effects OR (1.16; 95% CI 0.23 to 5.95) is smaller and less skewed. The heterogeneity suggested by this randomeffects and fixed-effect difference had an I² of 50% though as event count was low in Edwards 1988; this under-represents the differences between the two trials regarding mortality. In contrast to Costa 2003, the experimental penicillin group in Edwards 1988 was favoured with 1 versus 3 deaths though it did not reach statistical significance.

Only one trial reported days of hospitalisation without significant effect (8.9 versus 8.8 days) (MD 0.10 days, 95% CI -0.83 to 1.03) (Analysis 1.2) (Costa 2003). Days of clinical illness were decreased incorporating data from two of the trials (McClain 1984; Watt 1988). This reached statistical significance under fixed-effect modelling; however, under random-effects modelling, the

statistical significance was lost (fixed-effect: MD -2.13 days, 95% CI -2.46 to -1.80; random-effects: MD -4.04 days, 95% CI -8.66 to 0.58) (Analysis 1.3). I² for ratio of true heterogeneity in the outcome days of clinical illness was high (81%). The two incorporated trials varied in several ways. One included presumably immune troops in a carefully monitored setting, while the other assessed relatively severe disease among an endemic population.There was no difference in days of fever (MD 0.30, 95% CI -1.26 to 1.86) (Analysis 1.5) (Edwards 1988). Three trials reported that therapy markedly decreased subsequent isolation of leptospires from urine, though sufficient data were not available to incorporate this outcome in our analysis (McClain 1984; Edwards 1988; Watt 1988).

Cephalosporin versus penicillin

This comparison was explored in two trials (Panaphut 2003; Suputtamongkol 2004). Death and days of fever were assessable across the trials, though for both outcomes the size of the estimate of effect was small and did not reach statistical significance (MD -0.03 days, 95% CI -0.09 to 0.03) (Analysis 2.2).

Results for death did not vary substantively with missing data analysis (poor outcome scenario: OR 0.65, 95% CI 0.23 to 1.87; good outcome scenario: OR 0.72, 95% CI 0.23 to 2.21; extreme case scenario favouring cephalosporin: OR 0.56, 95% CI 0.19 to 1.64; extreme case scenario favouring penicillin: OR 0.84, 95% CI 0.28 to 2.58) (Analysis 2.1). While I² was low in the analysis of death representing a low risk for heterogeneity, risk was high for days of fever with an I² of 94%.

While both of these trials explored severe leptospirosis, their definitions of such as well as their populations differed. Pooling of these results may not be valid.

Doxycycline versus penicillin

This comparison was explored ina single trial (Suputtamongkol 2004). There was no appreciable difference in either death (poor outcome scenario: OR 0.54, 95% CI 0.10 to 3.02; good outcome scenario: OR 1.10, 95% CI 0.15 to 8.00) (Analysis 3.1) or days of fever within this trial (MD 0.00 days, 95% CI -0.25 to 0.25) (Analysis 3.2).

Azithromycin versus doxycycline

This comparison also was explored in a single trial (Phimda 2007). Among the subset of patients who had confirmed leptospirosis time to defervescence was not significantly different between the two groups, median 45 hours (range 8 to 118) in the doxycycline group, 40 hours (range 8 to 136) in the azithromycin group. Data were not available to analyse mean difference. The authors reported the fraction of participants with leptospirosis who became afebrile within 48 hours of initiation of therapy (Analysis 4.1). Odds of becoming afebrile quickly were similar in the two intervention groups (OR 1.51, 95% CI 0.57 to 4.00). Severe outcomes were not observed.

Cephalosporin versus doxycycline

This comparison was explored in a single trial (Suputtamongkol 2004). There was no appreciable difference in death (poor outcome scenario: OR 0.45, 95% CI 0.04 to 5.1; good outcome scenario: OR 0.18, 95% CI 0.01 to 3.80) (Analysis 5.1).

Adverse events

No adverse events were reported as attributed to cephalosporin therapy. In the discussion of Costa 2003, the authors commented



that 4% of patients who died did so in the first three days of their enrolment with a trend towards earlier death when it did occur in the group receiving penicillin. As above noted, the trend for increased death in the intervention group did not reach statistical significance and was diminished when incorporating randomeffects modelling in the setting of study heterogeneity. This was the only trial to report dialysis rates, a pre-defined primary outcome of interest in this review. Again, statistical significance was not reached, but in that trial the estimate of effect favoured the placebo group with regards to need for dialysis. The baseline characteristics table in that trial revealed a differential rate of severe renal failure with serum creatinine levels greater than 3 mg/dL (approximately 265 µmol/L) in 33% of patients in the penicillin group and 28% of patients in the placebo group. It was not possible from the available data to assess whether risk of dialysis explained the trend towards increased death nor to appreciate to what extent this 5% difference in initial renal involvement explained the trend towards dialysis. Edwards 1988 et al reported that they employed an early peritoneal dialysis strategy in renal failure within their trial. Consequently, their data was included in the analysis with Costa 2003 (Analysis 1.4). Heterogeneity between these two studies was low for this outcome, I² of 0 and a result tending to favour the control group (OR 1.54, 95% CI 0.91 to 2.60). Due to the possibility that the professed Edwards 1988 early dialysis strategy was unevenly applied, missing data analysis favouring the extreme case scenarios were employed to test the potential impact on their trial. In neither case was statistical significance achieved (extreme case favouring penicillin: OR 0.39, 95% CI 0.01 to 14.86, I² 84% (used randomeffects modelling); extreme case favouring control: OR 3.92, 95% CI 0.40 to 38.43; I² 63% (used random-effects modelling)). One excluded trial asserted that no difference was present in frequency or severity of renal injury in treated as compared with untreated patients (Hall 1951), though it investigated a heterogenous group of therapies. Edwards 1988 reported a single Jarisch-Herxheimer reaction in a patient three hours after administration of penicillin. This trial also reported iritis though it occurred in two instances in the placebo group and in only one instance in the therapy group.

A trial of azithromycin versus doxycycline for treatment of all comers suspected of either leptospirosis or scrub typhus demonstrated two cessations of therapy for adverse events in the doxycycline group (one patient with rash and the other with severe vomiting), but none in the azithromycin group (Phimda 2007). Proportions of adverse events also were higher in the doxycycline group, occurring in 28% versus 11% of patients. Thirtyseven of the 40 events in the doxycycline group were mild to moderate gastrointestinal complaints, while one complaint of rash in the doxycycline group and two in the azithromycin group were reported. Two events of dizziness were reported only in the doxycycline group. The trial by Phimda 2007 et al did not contribute information related to dialysis requirements. An included trial also assessed gastrointestinal complaints related to doxycycline (McClain 1984). No cessations of therapy due to adverse events were reported by McClain 1984 et al. While the trial did not provide comparative proportions of adverse events, it reported mean duration of gastrointestinal complaints among enrollees in both groups of the trial. Those in the placebo group reported a mean 2.1 +/- 0.5 days of gastrointestinal upset in contrast to 1.1 +/-0.3 days in the doxycycline group.

DISCUSSION

Summary of main results

The only result to achieve statistical significance (valid estimate of effect across its 95% CI or P < 0.05), approximately a two-day reduction in the number of days of clinical illness amongst patients on antibiotic therapy in contrast with placebo, lost statistical significance when assessed with random-effects modelling indicated by the apparent study heterogeneity. The effect may be greater for severe disease. Neither a choice of antibiotics versus placebo nor cephalosporin versus penicillin statistically significantly impacted patient mortality. Differences in assessable outcomes between different antibiotic choices were small. Some authors asserted that earlier therapy resulted in improved results, but supporting data were not reported.

Doxycycline-associated gastrointestinal complaints dominated the adverse events in a single excluded study. While this was not mirrored in the relevant included trials, it is consistent with findings on a review of antibiotic use for prophylaxis against leptospirosis (Brett-Major 2009). Dialysis was more common among penicillin recipients than those who received placebo (Costa 2003; Edwards 1988). The result did not reach statistical significance. While some authors argue that a threshold of P < 0.1 may be more appropriate in this type of analysis in order to account for the effect of unreported data and publication bias on sensitivity (Leandro 2005), the P value for this analysis result was 0.11 and the convention remains P < 0.05. Additionally, this finding may be confounded by an increased proportion of baseline severe renal dysfunction in the penicillin group (Costa 2003).

Overall completeness and applicability of evidence

Multiple databases without language restrictions were explored in the generation of this review. While an explicit test for publication bias was relevant only for the outcome days of clinical illness for antibiotics versus placebo, it was inconclusive.

Several interesting observational studies and clinical trials have been executed on the treatment of leptospirosis over the past 60 years. Nonetheless, the breadth of literature remains pleomorphic. Four of the seven included trials in this review purported to assess therapy in severe leptospirosis. However, in most cases clear definitions of severity were not provided and the most severe presenting patients - those with anuria, obtundation - excluded. In one trial, roughly 90% of patients exhibited jaundice at baseline while severe renal failure was present in 33% and 28% of the penicillin and placebo groups, respectively, with more mild renal failure present in over 90% (Costa 2003). Another trial reported baseline jaundice in 43% and 47% of the cephalosporin and penicillin groups, respectively, and approximately 80% with some renal failure in both groups (Panaphut 2003). Some renal failure was present in 41%, 28%, 40% of the penicillin, doxycycline, cefotaxime groups with 32%, 25%, and 35% prevalences of jaundice, respectively (Suputtamongkol 2004). In this trial doxycycline was favoured with patients of lower severity of illness against other antibiotic selections. These three trials with Edwards 1988 contributed all of the mortality events. The trial of troops did not seem to have significant baseline severity though it was not detailed in the report (McClain 1984). Duration of illness at presentation also varied across trials. Though, one trial had a high rate of exclusion due to death within 24 hours and

Antibiotics for leptospirosis (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

another reported that most patients had more than five days of symptoms, both suggesting later disease (Watt 1988; Costa 2003).

Despite a lack of evidence of the utility of antibiotic therapy for leptospirosis, penicillin, cephalosporins, and doxycycline are commonly employed therapies in the management of leptospirosis. Despite its higher cost, interest in azithromycin against *Leptosira* spp. is increasing due to its broad activity against confounding pathogens, low mean inhibitory concentration (MIC), and fewer mild adverse events (Phimda 2007; Ressner 2008).

Penicillin has been tested against placebo for the treatment of severe leptospirosis. However, benefits were uneven across the patient populations and the nature of adverse events from therapy in severe disease is not clear. This makes a robust risk-benefit analysis difficult. Further placebo controlled trials are needed.

Quality of the evidence

The potential for bias in the trials was high and may reflect the long period of time across which both the included and excluded trials were conducted, consequently the literature practices of their times. The most problematic issues were blinding and disclosure of the roles of commercial partners. Blinding was particularly difficult to accomplish in these trials because antibacterial agents against gram negative pathogens were available to treatment teams when not employing a cephalosporin for the trial intervention. The lack of a placebo for these anti-gram negative pathogen agents such as gentamicin increased variability in the trials and possibly introduced confounding, though use was generally well distributed between groups. The potential for misclassification of patients during intake into these types of trials is high. Edwards 1988, for instance, used clinical criteria for dengue as an exclusion criteria. However, clinical confusion between leptospirosis and dengue can be high (LaRocque 2005).

Potential biases in the review process

Random errors are particularly problematic in reviews in which few trials are contributing events to individual outcomes. Only one author of two of the trials responded to this review when a draft of this manuscript was sent 15 May 2011, Dr. Yupin Suputtamongkol. His clarification was very helpful for two of the reviewed trials (Suputtamongkol 2004; Phimda 2007). While only three additional candidate references were identified on serial electronic literature searches between initiation and repeat of the search, some relevant pre-MEDLINE studies later excluded were identified only by bibliographic or hard copy Cochrane Hepato-Biliary Group file review. As in any such review, relevant literature might have been missed. Publication bias towards those trials which show affirmative results is a well recognised concern. However, several negative trials for most outcomes were present in both the included and excluded trials.

Agreements and disagreements with other studies or reviews

The breadth of available data has evolved since the previous iteration of this review (Costa 2003; Panaphut 2003; Suputtamongkol 2004; Phimda 2007). That review identified 12

relevant records meriting full-text evaluation and incorporated five trials (Guidugli 2000). Like the earlier review, this review did not reveal evidence compelling the use of antibiotic therapy for leptospirosis.

AUTHORS' CONCLUSIONS

Implications for practice

Insufficient evidence is available to advocate for or against the use of antibiotics in the therapy for leptospirosis. Among survivors who were hospitalised for leptospirosis, use of antibiotics for leptospirosis may have decreased the duration of clinical illness by two to four days though this result was not statistically significant. Relatively severe and possibly late leptospirosis patients may have increased dialysis when penicillin is used rather than placebo, but this result was driven by a single trial, the estimate of effect was small and it did not reach statistical significance. If a clinician chooses to utilize antibiotic therapy, there is no evidence to suggest that selection of penicillin, doxycycline, or cephalosporin impacts mortality or duration of fever.

Implications for research

Further placebo controlled trials exploring antibiotic therapy for carefully staged leptospirosis is needed. The question of whether or not antibiotics should be used in leptospirosis remains open, as does the optimal timing and severity in which to employ such therapy. Potential trials could include a wider array of tested agents tried against placebo for therapy against leptospirosis. Careful planning in such trials should be done for disease severity, targeted outcomes such as minimisation of lost work days, prevention of hospitalisation, dialysis, and in areas where pulmonary manifestations are dominant, ventilation as well as death. If antibiotics confer true risk in leptospirosis therapy, their assessment might include factorial research designs which simultaneously assess adjunctive therapies which might mitigate their effect. In the future, trials ought to be conducted with less risk of systematic errors (bias) and less risk of random errors (play of chance) and ought to be reported according to the CONSORT guidelines (www.consort-statement.org).

ACKNOWLEDGEMENTS

We thank the authors of the previous Cochrane review on this topic for their work assessing the available literature on antibiotic therapy for leptospirosis - F Guidugli, AA Castro, and AN Atallah. Support from the Cochrane Hepato-Bilary Group remains outstanding from both the Trials Search Co-ordinator, Ms. Sarah Klingenberg, and Dimitrinka Nikolova, Managing Editor.

Protocol

Peer Reviewers: Vanja Giljaca, Croatia; Goran Poropat, Croatia. Contact Editor: Christian Gluud, Denmark.

Review

Peer Reviewers: Vanja Giljaca, Croatia; Goran Poropat, Croatia. Contact Editor: Ronald Koretz, United States; Christian Gluud, Denmark.

REFERENCES

References to studies included in this review

Costa 2003 {published data only (unpublished sought but not used)}

* Costa E, Lopes AA, Sacramento E, Costa YA, Matos ED, Baretto M, et al. Penicillin at the late stage of leptospirosis: a randomized controlled trial. *Revista do Instituto de Medicina Tropical de Sao Paulo* 2003;**45**(3):141-5.

Edwards 1988 {published data only}

* Edwards CN, Nicholson GD, Hassell TA, Everard CO, Callender J. Penicillin therapy in icteric leptospirosis. *American Journal of Tropical Medicine and Hygiene* 1988;**39**(4):388-90.

McClain 1984 {published data only}

* McClain BL, Ballou WR, Harrison SM, Steinweg DL. Doxcycyline therapy for leptospirosis.. *Annals of Internal Medicine* 1984;**100**(5):696-8.

Panaphut 2003 {published data only (unpublished sought but not used)}

* Panaphut T, Domrongkitchaiporn S, Vibhagool A, Thinkamrop B, Susaengrat W. Ceftriaxone compared with sodium penicillin for treatment of severe leptospirosis. *Clinical Infectious Diseases* 2003;**36**:1507-13.

Phimda 2007 {published and unpublished data}

* Phimda K, Hoontrakul S, Suttinont C, Chareonwat S, Losuwanaluk K, Chueasuwanchai S, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. *Antimicrobial Agents and Chemotherapy* 2007;**51**(9):3259-63.

Suputtamongkol 2004 {published and unpublished data}

* Suputtamongkol Y, Niwattayakul K, Suttinont C, Losuwanaluk K, Limpaiboon R, Chierakul W, et al. An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. *Clinical Infectious Diseases* 2004;**39**:1417-24.

Watt 1988 {published data only}

* Watt G, Padre LP, Tuazon ML, Calubaquib C, Santiago E, Ranoa CP, et al. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. *Lancet* 1988;**1**(8583):433-5.

References to studies excluded from this review

Doherty 1955 {published data only}

Doherty RL. A clinical study of leptospirosis in North Queensland. *Australas Annals of Medicine* 1955;**4**(1):53-63.

Fairburn 1956 {published data only}

Fairburn AC, Semple SJG. Chloramphenicol and penicillin in the treatment of leptospirosis among British troops in Malaya. *Lancet* 1956;**270**(6906):13-6.

Hall 1951 {*published data only*}

Hall HE, Hightower JA, Diaz Rivera R, Byrne RJ, Smadel JE, Woodward TE. Evaluation of antibiotic therapy in human leptospirosis. *Annals of Internal Medicine* 1951;**35**(5):981-98.

Munnich 1972 {published data only}

Munnich D, Lakatos M. Treatment of leptospirosis with Semicillin. *Therapia Hungarica (English Edition)* 1972;**20**(4):152-5.

Russell 1958 {published data only}

Russell RW. Treatment of leptospirosis with oxytetracycline. *Lancet* 1958;**2**(7057):1143-5.

Additional references

Bharti 2003

Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. Leptospirosis: a zoonotic disease of global importance. *The Lancet Infectious Diseases* 2003;**3**(12):757-71.

Brett-Major 2009

Brett-Major DM, Lipnick RJ. Antibiotic prophylaxis for leptospirosis. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: 10.1002/14651858.CD007342.pub2]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**:629-34.

Gluud 2011

Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2011, Issue 8. Art. No.: LIVER.

Hadad 2006

Hadad E, Pirogovsky A, Bartal C, Gilad J, Barnea A, Yitzhaki S, et al. An outbreak of leptospirosis among Israeli troops near the Jordan River. *The American Journal of Tropical Medicine and Hygiene* 2006;**74**(1):127-31.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Hollis 1999

Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. *BMJ* (*Clinical Research Ed.*) 1999;**319**:670-4.

ICH-E3 1995

ICH harmonized tripartite guideline. Guideline on structure and content of clinical study reports (E3). Geneva: International Conference on Harmonization of Technical Requirements

Antibiotics for leptospirosis (Review)

for Registration of Pharmaceuticals for Human Use. http://

www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Efficacy/E3/Step4/E3_Guideline.pdf 1995 (accessed 16 May 2011).

Trusted evidence.

Informed decisions. Better health.

ICH-GCP 1996

ochrane

ICH harmonised tripartite guideline. Guideline for good clinical practice E6 (R1). Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/ Step4/E6_R1__Guideline.pdf 1996 (accessed 16 May 2011).

Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Annals of Internal Medicine* 2001;**135**:982-9.

LaRocque 2005

LaRocque RC, Breiman RF, Ari MD, Morey RE, Janan FA, Hayes JM, et al. Leptospirosis during dengue outbreak, Bangladesh. *Emerging Infectious Diseases* 2005;**11**(5):766-9.

Leandro 2005

Leangro G. Meta-analysis in Medical Research: The Handbook for the Understanding and Practice of Meta-Analysis. Oxford: Blackwell Publishing Ltd., 2005.

Liverpool 2008

Liverpool J, Francis S, Liverpool CE, Dean GT, Mendez DD. Leptospirosis: case reports of an outbreak in Guyana. *Annals of Tropical Medicine and Parasitology* 2008;**102**(3):239-45.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. *Lancet* 1998;**352**:609-13.

Pappas 2008

Pappas G, Papadimitriou P, Siozopoulo V, Christou L, Akritidis N. The globalization of leptospirosis: worldwide incidence trends. *International Journal of Infectious Diseases* 2008;**12**(4):351-7. [MEDLINE: 18055245]

Ressner 2008

Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, et al. Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. *Antimicrobial Agents and Chemotherapy* 2008;**52**(8):2750-4.

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Costa 2003

Methods

Prospective, single site, randomised, clinical trial.

RevMan 2011 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Royle 2003

Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. *International Journal of Technology Assessment in Health Care* 2003;**19**(4):591-603.

Russell 2003

Russell KL, Montiel Gonzalez MA, Watts DM, Lagos-Figueroa RC, Chauca G, Ore M, et al. An outbreak of leptospirosis among Peruvian military recruits. *The American Journal of Tropical Medicine and Hygiene* 2003;**69**(1):53-7.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**:408-12.

Sejvar 2003

Sejvar J, Bancroft E, Winthrop K, Bettinger J, Bajani M, Bragg S, et al. Leptospirosis in "Eco-Challenge" athletes, Malaysian Borneo, 2000. *Emerging Infectious Diseases* 2003;**9**(6):702-7.

WHO 2003

World Health Organization. International Leptospirsos Society. Human Leptospirosis: Guide for Diagnosis, Surveillance and Control. World Health Organization, 2003.

Wood 2008

Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ (Clinical Research Ed.)* 2008;**336**:601-5.

References to other published versions of this review

Guidugli 2000

Guidugli DF, Castro AA, Atallah AN. Antibiotics for treating leptospirosis. *Cochrane Database of Systematic Reviews* 2000, Issue 2. [DOI: 10.1002/14651858.CD001306]

* Indicates the major publication for the study

Antibiotics for leptospirosis (Review)



Costa 2003 (Continued)	
Participants	All comers to a regional hospital with four days of symptoms and a WHO leptospirosis score of at least 26, predominantly men in the 3rd to 5th decade of life. 247 of 253 patients had a positive macroscop- ic slide agglutination test for leptospirosis, 45 a micro-agglutination test (MAT) and 17 a positive blood culture for <i>Leptospira</i> .
Interventions	PCN 1 million units parentally every four hours for seven days against no targeted antimicrobial thera- py.
Outcomes	Death, length of hospitalisation, and dialysis.
Notes	Approximately 94% of their patients in both groups had icterus suggesting that this represented a trial of therapeutic efficacy in late disease. Multiple biomarkers were collected at days 0, 3, and 7 from admission. Authors reported no difference between groups but did not discuss changes over time.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	P 142, "each patient and was randomly assigned to" though no descrip- tion of method of randomisation to include sequence generation was provid- ed.
Allocation concealment (selection bias)	Unclear risk	Not discerned.
Blinding (performance bias and detection bias) All outcomes	High risk	P 143, "Even though in the present study the treating physicians were not blind to the patient assignment"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not discerned.
Selective reporting (re- porting bias)	Low risk	P 143, Table 2 outcome data for death calculated for same numbers as shown in Table 1 Demographics.
Other bias	Low risk	P 144, trial executed using public grants.

Edwards 1988

Methods	Prospective, single site, randomised, clinical trial.	
Participants	All comers for who there was a clinical suspicion of icteric leptospirosis later diagnosed through culture or convalescent titer rise. They were predominantly men in the fourth decade of life.	
Interventions	2 million units of intravenous penicillin every 6 hours for 5 days or saline.	
Outcomes	Time to defervescence, clearance of urine culture, normalisation of laboratory values, renal failure, and death.	
Notes	This trial targeted severe leptospirosis. Serum biomarkers collected on admission had high standard deviations though reportedly 7 of 38 and 8 of 41 patients in the penicillin and placebo groups, respectively, had renal failure on admission.	

Risk of bias

Antibiotics for leptospirosis (Review)



Edwards 1988 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	P 388, while the method of randomisation is not explicitly stated, authors reference a source with several approaches to randomisation.
Allocation concealment (selection bias)	Unclear risk	Not discerned.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	P. 388, the trial used a saline placebo and stated that the investigator involved in allocation was not involved in management, but there is no explicit mention of blinding.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not discerned.
Selective reporting (re- porting bias)	Low risk	Death was reported. While renal failure and not dialysis was reported, authors stated that they employed early peritoneal dialysis in renal failure so that assertion applied in the dialysis analysis incorporating missing data outcome scenarios.
Other bias	Unclear risk	Not discerned.

McClain 1984

Methods	Prospective, single site, blinded, randomised, clinical trial.
Participants	Troops presenting for care with fever and subsequent verified leptospirosis serology or culture at the Jungle Operations Training Center, Panama. 26 of 29 patients had positive blood cultures for <i>Leptospira</i> .
Interventions	Seven day course of twice daily doxycyline hyclate 100 mg or placebo.
Outcomes	Assessed clearing of cultures and resolution of fever.
Notes	This trial evaluated therapeutic efficacy in early disease.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	P. 697, "packets were randomly assigned by computer to contain doxycycline hyclate or lactose"
Allocation concealment (selection bias)	Low risk	P. 696, "assigned sequentially numbered packets of tablets that were identical in appearance"
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not discerned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	P. 697, "after discharge, patients were followed every other day for 1 week and once a week thereafter for 2 weeks"

Antibiotics for leptospirosis (Review)

McClain 1984 (Continued)

Selective reporting (re- porting bias)	Unclear risk	Pre-defined study outcomes inconsistent with those listed in the Types of Out- comes section, though death did not occur and was discernible from the pub- lished data.
Other bias	Unclear risk	Not discerned.

Methods	Prospective, single-site, randomised, comparative trial.		
Participants	Adult patients presenting with severe leptospirosis, predominantly men in the 4th through 6th decades of life with an average WHO leptospirosis score 23 to 24. Laboratory confirmation by titer or culture was required for inclusion in analysis. All 173 had a positive rapid test for leptospirosis, only 126 were con- firmed by MAT.		
Interventions	Antibiotics for seven days or until afebrile for 48 hours: ceftriaxone 1gm parenterally daily or penicillin 1.5 million units every 6 hours with the addition of gentamicin if also suspicious for gram negative sep- sis.		
Outcomes	Death, duration of fever, and renal failure.		
Notes	All deaths occurred within five days of hospitalisation - 5 pulmonary haemorrhage, 2 multi-organ fail- ure, 1 severe hyperK, uraemic encephalopathy, 1 ARDS. However, causes are not delineated by treat- ment group. It is unclear for how long patients who received penicillin also received gentamicin. Those patients treated with ceftriaxone had higher rates of prior treatment with doxycycline and penicillin. Standard deviation on mean days of fever were not provided so substituted the range of absolute dif- ference.		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	P. 1508, "patients were randomly allocated into 2 groups by stratified-block randomisation"
Allocation concealment (selection bias)	Low risk	P. 1508, "each label was enclosed in a sealed, opaque envelope"
Blinding (performance bias and detection bias) All outcomes	High risk	P. 1508, the ceftriaxone and penicillin groups had different medication admin- istration regimens, each day versus four times daily. The addition of gentam- icin among penicillin recipients when gram negative sepsis had not been ex- cluded increased the likelihood that observers were aware of treatment allo- cation.
Incomplete outcome data (attrition bias) All outcomes	Low risk	p1509, causes for exclusion from the trial and analyses were clearly enumer- ated. P 1509-10, "For those who did not return for follow-up after being dis- charged from the hospital, data regarding their physical conditions after dis- charge were obtained individually by direct contact of local health care per- sonnel. All of the patients [who had not returned] completely recovered from the illness."
Selective reporting (re- porting bias)	Unclear risk	P. 1510, "Ten patients (5 in each group) died, for an overall case mortality rate, 5.8%" which is correct for the number of patients reported to have been in- cluded. While burden of renal failure was reported as was an overall dialysis rate of more than 10 per cent, dialysis was not discernible in each trial arm.

Antibiotics for leptospirosis (Review)



Panaphut 2003 (Continued)

Other bias

Unclear risk

P. 1507, Ceftriaxone was provided by Siam Pharmaceutical. No statement regarding the role of funding agents was provided.

Methods	Prospective, multi-site, randomised, clinical trial.	
Participants	Patients over 14 years of age with suspected leptospirosis or scrub typhus as described by acute fever without clear source of infection and able to tolerate oral antibiotic therapy. Among all randomised patients (pre-diagnosis), this study had the lowest ratio of men:women of approximately 2.5:1, predominantly in the 4th decade of life. Laboratory confirmation by titer or culture was required for inclusion in analysis. 10 patients were identified by culture, 45 by four-fold rise in convalescent titer and 1 by a single titer of at least 1:400.	
Interventions	Oral doxycycline 200mg for 1 dose then 100 mg every 12 h for 7 days, or azithromycin 1 g for 1 dose then 500 mg once daily for 2 days.	
Outcomes	The primary outcome for this trial was rate of cure defined by afebrile for 48 hours.	
Notes	This trial was designed as a non-inferiority trial of azithromycin against doxycycline among febrile patients. Data presented here was provided on correspondence with the senior author, Dr. Suputta-mongkol, who verified for the authors results among those enrolled patients with laboratory confirmed leptospirosis.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	P. 3260, "Independent, computer-generated, simple random allocation se- quences were prepared for each study hospital by the investigator team in Bangkok."
Allocation concealment (selection bias)	Low risk	P. 3260, "These were sealed in an opaque envelope and numbered. The inves- tigator in each study hospital assigned study participants to their treatment groups after opening the sealed envelope."
Blinding (performance bias and detection bias) All outcomes	High risk	P. 3260, the two intervention options were dosed differently and were not used in conjunction with placebo.
Incomplete outcome data (attrition bias) All outcomes	High risk	P. 3260, confirmation of leptospirosis depended upon analysis of both acute and convalescent sera. 89 of 296 patients who were randomised were not as- sessed at 1 to 2 weeks following discharge. For 23 of these patients nearer term sera 3 to 5 days following admission was available and used for assessing interval titer.
Selective reporting (re- porting bias)	High risk	Pre-defined outcome was time to defervescence and whether outcomes in the Types of Outcomes section were completely discerned was not discernible.
Other bias	Unclear risk	Not discerned.

Prospective, multi-site, randomised, comparative trial.
Adults with less than 15 days of fever and laboratory confirmation of leptospirosis (all but two with both serology and culture positivity). In contrast to the other trials, roughly 3 of 4 (rather than 9 of 10) of the participants were men. Age ranges included mid-late adolescents and geriatric patients though median was in the 4th decade of life.
This trial assessed three treatment groups of parenteral induction therapy with penicillin 1.5 million units every six hours, cefotaxime 1gm six hours, or doxycycline loaded with 200 mg then 100 mg twice daily; then, once afebrile and tolerating oral therapy, penicillin and cefotaxime patients were ran- domised to either amoxicillin 2 g per day or doxycycline 200 mg per in divided doses, while those who started with doxycycline transitioned to oral doxycycline therapy. Total course of therapy was 7 days.
Death and duration of fever.
Two patients in the penicillin group and one in the cefotaxime group were excluded for uncertain out- comes. They were included in these analyses as deaths. While the researchers prospectively char- acterised disease severity at inclusion, outcome data were not stratified by disease severity. The re- searchers assert that in multi-variate analysis disease severity (at least two organs with dysfunction) and not antibiotic choice impact days of fever, though only level of statistical significance and not strength of effect are provided. As standard deviation was not provided for the duration of fever, an over estimate based upon the range and presuming near normal distribution were used.

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	P. 1418, "The independent, computer-generated random allocation sequences were prepared"
Allocation concealment (selection bias)	Low risk	P. 1418, "sealed in an opaque envelope, and the envelopes were numbered."
Blinding (performance bias and detection bias) All outcomes	High risk	P. 1418, each administered regimen differed and required investigator knowl- edge of regimen in order to adjust for the possible presence of gram negative sepsis.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	P. 1419 Table 1, while the number of excluded patients due to uncertain out- come is provided, details and success of the following component of the pro- tocol is not disclosed.
Selective reporting (re- porting bias)	Unclear risk	Death was reported. Dialysis was not discernible.
Other bias	Unclear risk	Not discerned.

Watt 1988	
Methods	Prospective, single site, randomised, double-blind, placebo clinical trial.
Participants	Patients over 16 years of age presenting to a national infectious diseases hospital with suspected lep- tospirosis and either a positive rapid IgM-based immunosorbent assay or a positive single serovar mi- croagglutination assay, all later confirmed with multi-serovar based serologic assays or culture. Only 7 participants had positive <i>Leptospira</i> cultures. The patients were predominantly men 20 to 40 years of age.

Antibiotics for leptospirosis (Review)

Watt 1988 (Continued)

Interventions	1,500,000 units of parenteral sodium penicillin G administered four times daily for 7 days or a normal saline placebo.
Outcomes	Durations of fever and serum creatinine rise.
Notes	The trial was intended to focus on more severe disease but anuric patients or those so severely ill that they could not provide consent were excluded, and no deaths or requirements for dialysis occurred. Se- cond infections were disqualifying, but the screening algorithm for potential co-endemic diseases was not provided. Patients were categorised as severely infected if serum creatinine was > 177 µmol/L or the patients were clinically jaundiced.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	P. 433, "randomly assigned to receive sodium penicillin G or placebo," method of randomisation not disclosed.
Allocation concealment (selection bias)	Unclear risk	Not discerned.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not discerned.
Incomplete outcome data (attrition bias) All outcomes	Low risk	P. 433, "patients were followed up a week and a month after discharge;" p434, all leptospirosis patients completed therapy.
Selective reporting (re- porting bias)	High risk	Pre-defined outcome was time to defervescence and serum creatinine and whether outcomes in the Types of outcomes section were completely discerned was not discernible.
Other bias	Unclear risk	Not discerned.

ARDS = acute respiratory distress syndrome. IgM = immunoglobulin M. h = hour. g = gram. μmol/L = micromole.

> = greater than.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Doherty 1955	This retrospective study assessed 115 cases of leptospirosis among Australian troops. The study at- tempts an analysis of the impact of increasing dose of penicillin on shortening of the duration of fever. It suggests mild decreases (1 to 2 days) of duration of fever and well describes the fever curve of untreated and treated leptospirosis. It did not contribute information on adverse events.
Fairburn 1956	This study prospectively assessed British troops deployed to an endemic area (Malaya). Ill troops with suspected leptospirosis all of who were mildly ill were divided among three groups: control, penicillin therapy or chloramphenicol therapy. A case definition for leptospirosis was not provid- ed. Confirmation by a serologic method or culture was reported in 50 of the 83 patients. However, the results could not be explored based upon this confirmation and serologic categorizations and

Antibiotics for leptospirosis (Review)

Study	Reason for exclusion
	methods have evolved considerably since study execution. No information on randomisation was provided. Adverse events of therapy were not discussed.
Hall 1951	This study reports treatment performance in 67 cases of leptospirosis in Puerto Rico. Chloram- phenicol, aureomycin, penicillin, terramycin, streptomycin, aureomycin and streptomycin, cor- tisone and aureomycin were employed. The article implies that these treatment groups were un- dertaken prospectively and sequentially in block, however it acknowledges variability in how the treatments were applied. Also it was unclear whether twelve contemporary controls were used in their analyses. With regards to adverse events, the study asserted that there was no difference in the frequency or severity of renal injury between treated and untreated patients.
Munnich 1972	This is a single arm observational study of an oral ampicillin formulation of ampicillin in the treatment of leptospirosis. The study did not report any adverse events. The observation-al series appears to have continued with a related amoxycillin formulation in Chemotherapy 1976;22(6):372-80.
Russell 1958	This study prospectively assessed British troops deployed to an endemic area (Malaya). Ill troops with suspected leptospirosis divided among two groups: ascorbic acid placebo or parenteral oxyte- tracycline. Definition for leptospirosis in a patient was not provided. Confirmation by a serolog- ic method or culture was reported to have occurred in all 52 patients. However, the results could not be explored based upon this confirmation, and serologic categorisations and methods have evolved considerably since study execution. The patients were alternately placed in each group without randomisation. This test drug is no longer employed in common practice.

DATA AND ANALYSES

Comparison 1. Antibiotics versus placebo

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Death	4	403	Odds Ratio (M-H, Random, 95% CI)	1.16 [0.23, 5.95]
2 Days of hospitalisation	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 Days of clinical illness	2	71	Mean Difference (IV, Random, 95% CI)	-4.04 [-8.66, 0.58]
4 Dialysis employed	2	332	Odds Ratio (M-H, Fixed, 95% CI)	1.54 [0.91, 2.60]
5 Days of fever	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

Analysis 1.1. Comparison 1 Antibiotics versus placebo, Outcome 1 Death.

Study or subgroup	Antibiotics	Placebo		(Odds Ratio	•		Weight	Odds Ratio
	n/N	n/N		M-H, Random, 95% CI					M-H, Random, 95% CI
Costa 2003	15/125	8/128				_		68.35%	2.05[0.83,5.01]
Edwards 1988	1/38	3/41			•			31.65%	0.34[0.03,3.44]
	Fav	vours antibiotics	0.01	0.1	1	10	100	Favours placebo	

Antibiotics for leptospirosis (Review)



Trusted evidence. Informed decisions. Better health.

Study or subgroup	Antibiotics	Placebo	Odds Ratio					Weight	Odds Ratio
	n/N	n/N		м-н,	Random, 9	5% CI			M-H, Random, 95% CI
McClain 1984	0/14	0/15							Not estimable
Watt 1988	0/23	0/19							Not estimable
Total (95% CI)	200	203		-				100%	1.16[0.23,5.95]
Total events: 16 (Antibiotics),	11 (Placebo)								
Heterogeneity: Tau ² =0.81; Chi	i ² =2.01, df=1(P=0.16); I ² =50.2	8%							
Test for overall effect: Z=0.18((P=0.86)								
	Fa	vours antibiotics	0.01	0.1	1	10	100	Favours placebo	

Analysis 1.2. Comparison 1 Antibiotics versus placebo, Outcome 2 Days of hospitalisation.

Study or subgroup	or subgroup Antibiotics			Placebo		Меа	an Differe	Mean Difference		
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI			СІ		Fixed, 95% Cl
Costa 2003	125	8.9 (3.9)	128	8.8 (3.6)						0.1[-0.83,1.03]
			Favours antibiotics		-4	-2	0	2	4	Favours placebo

Analysis 1.3. Comparison 1 Antibiotics versus placebo, Outcome 3 Days of clinical illness.

Study or subgroup	Ant	tibiotics	Placebo		Mean Difference		rence Weight		Weight	Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)		Rand	om, 95%	сі			Random, 95% CI
McClain 1984	14	5.6 (0.4)	15	7.7 (0.5)			+			59.54%	-2.1[-2.43,-1.77]
Watt 1988	23	4.7 (4.2)	19	11.6 (8.3)						40.46%	-6.9[-11.02,-2.78]
Total ***	37		34							100%	-4.04[-8.66,0.58]
Heterogeneity: Tau ² =9.29; Chi ²	=5.17, df=1(P=0	0.02); I ² =80.68%									
Test for overall effect: Z=1.72(P	=0.09)										
			Favou	urs antibiotics	-20	-10	0	10	20	Favours placebo)

Analysis 1.4. Comparison 1 Antibiotics versus placebo, Outcome 4 Dialysis employed.

Study or subgroup	Antibiotics	Placebo		Odds Ratio				Weight	Odds Ratio
	n/N	n/N		M-H	I, Fixed, 95%	CI			M-H, Fixed, 95% CI
Costa 2003	35/125	23/128				-		72.27%	1.78[0.98,3.22]
Edwards 1988	7/38	8/41		_	-			27.73%	0.93[0.3,2.87]
Total (95% CI)	163	169			•			100%	1.54[0.91,2.6]
Total events: 42 (Antibiotics), 3	81 (Placebo)								
Heterogeneity: Tau ² =0; Chi ² =0.	.98, df=1(P=0.32); I ² =0%								
Test for overall effect: Z=1.62(F	9=0.11)								
	Fa	avours antibiotics	0.05	0.2	1	5	20	Favours placebo	



Analysis 1.5. Comparison 1 Antibiotics versus placebo, Outcome 5 Days of fever.

Study or subgroup	Ar	ntibiotics		Placebo		Mea	an Differe	nce		Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Fi	xed, 95%	CI		Fixed, 95% Cl
Edwards 1988	38	6.9 (3.8)	41	6.6 (3.2)		-				0.3[-1.26,1.86]
				Favours antibiotics	-5	-2.5	0	2.5	5	Favours placebo

Comparison 2. Cephalosporin versus penicillin

Outcome or subgroup ti- tle	No. of studies	No. of par- ticipants	Statistical method	Effect size
1 Death	2	351	Odds Ratio (M-H, Fixed, 95% CI)	0.65 [0.23, 1.87]
2 Days of fever	2	348	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.09, 0.03]

Analysis 2.1. Comparison 2 Cephalosporin versus penicillin, Outcome 1 Death.

Study or subgroup	Cephalosporin	Penicillin		Odds Ratio			Weight	Odds Ratio	
	n/N	n/N		M-H	l, Fixed, 95%	6 CI			M-H, Fixed, 95% CI
Panaphut 2003	5/87	5/86			_			54.51%	0.99[0.28,3.54]
Suputtamongkol 2004	1/89	4/89	_	-				45.49%	0.24[0.03,2.2]
Total (95% CI)	176	175		-				100%	0.65[0.23,1.87]
Total events: 6 (Cephalosporir	n), 9 (Penicillin)								
Heterogeneity: Tau ² =0; Chi ² =1	18, df=1(P=0.28); I ² =15.53%								
Test for overall effect: Z=0.8(P	=0.42)								
	Favou	rs cephalosporin	0.01	0.1	1	10	100	Favours penicillin	

Favours cephalosporin Favours penicillin

Analysis 2.2. Comparison 2 Cephalosporin versus penicillin, Outcome 2 Days of fever.

Study or subgroup	Ceph	alosporin	Pe	nicillin		Mea	an Differen	ce		Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)		Fixed, 95% Cl				Fixed, 95% Cl	
Panaphut 2003	87	3 (0.2)	86	3 (0.2)			-			93.65%	0[-0.06,0.06]
Suputtamongkol 2004	88	2.5 (0.7)	87	3 (0.8)						6.35%	-0.5[-0.73,-0.27]
Total ***	175		173				•			100%	-0.03[-0.09,0.03]
Heterogeneity: Tau ² =0; Chi ² =17	7.16, df=1(P<0.0	0001); I ² =94.17%									
Test for overall effect: Z=1.08(P	=0.28)										
			Favours c	ephalosporin	-1	-0.5	0	0.5	1	Favours penie	cillin

Comparison 3. Doxycycline versus penicillin

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Death	1		Odds Ratio (M-H, Fixed, 95% CI)	Totals not selected
2 Days of fever	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

Analysis 3.1. Comparison 3 Doxycycline versus penicillin, Outcome 1 Death.

Study or subgroup	Doxycycline Penicillin				Odds Ratio		Odds Ratio	
	n/N	n/N		M	H, Fixed, 95%	CI		M-H, Fixed, 95% CI
Suputtamongkol 2004	2/81	4/89	_		-	- ,		0.54[0.1,3.02]
		Favours doxycycline	0.05	0.2	1	5	20	Favours penicillin

Analysis 3.2. Comparison 3 Doxycycline versus penicillin, Outcome 2 Days of fever.

Study or subgroup	Do	oxycycline	1	Penicillin		Me	an Differe	nce		Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Fi	i xed, 95 %	CI		Fixed, 95% CI
Suputtamongkol 2004	81	3 (0.8)	87	3 (0.8)						0[-0.25,0.25]
			Fa	vours doxycycline	-0.5	-0.25	0	0.25	0.5	Favours penicillin

Comparison 4. Azithromycin versus doxycycline

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Afebrile within 48 hours of initiation of therapy	1		Odds Ratio (M-H, Fixed, 95% Cl)	Totals not select- ed

Analysis 4.1. Comparison 4 Azithromycin versus doxycycline, Outcome 1 Afebrile within 48 hours of initiation of therapy.

Study or subgroup	Azithromycin	Doxycycline	Odds Ratio	Odds Ratio
	n/N	n/N	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Phimda 2007	23/35	19/34		1.51[0.57,4]
		Favours azithromycin 0.2	0.5 1 2	⁵ Favours doxycycline

Comparison 5. Cephalosporin versus doxycycline

Outcome or subgroup ti- tle	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Death	1		Odds Ratio (M-H, Fixed, 95% CI)	Totals not selected

Analysis 5.1. Comparison 5 Cephalosporin versus doxycycline, Outcome 1 Death.

Study or subgroup	Cephalosporin Doxycycline				Odds Ratio		Odds Ratio	
	n/N	n/N		M-H	, Fixed, 95	% CI		M-H, Fixed, 95% CI
Suputtamongkol 2004	1/88	2/81						0.45[0.04,5.1]
		Favours cephalosporin	0.01	0.1	1	10	100	Favours doxycycline

APPENDICES

Appendix 1. Search Strategies

Database	Span of Search	Search strategy				
The Cochrane Hepa- to-Biliary Group Con- trolled Trials Register	October 2011.	leptospir* AND (treat* OR therap*)				
Cochrane Cen-	Issue 3, 2011	#1 MeSH descriptor Anti-Bacterial Agents explode all trees				
tral Register of Controlled Trials		#2 treat* OR therap*				
(CENTRAL) in <i>The</i> Cochrane Library		#3 (#1 OR #2)				
		#4 MeSH descriptor Leptospirosis explode all trees				
		#5 leptospir*				
		#6 (#4 OR #5) #7 (#3 AND #6)				
MEDLINE (Ovid SP)	From 1948 to Octo-	1. exp Anti-Bacterial Agents/				
	ber 2011.	2. (treat* or therap*).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]				
		3. 1 or 2				
		4. exp Leptospirosis/				
		5. leptospir*.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]				
		6. 4 or 5				
	7. 3 and 6					
		8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, original title, ab- stract, name of substance word, subject heading word, unique identifier]				

Antibiotics for leptospirosis (Review)

Cochrane

Library

(Continued)		
· · ·		9. 7 and 8
EMBASE (Ovid SP)	From 1980 to October 2011.	1. exp antibiotic therapy/
		2. (treat* or therap*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
		3. 1 or 2
		4. exp leptospirosis/
		5. leptospir*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
		6. 4 or 5
		7. 3 and 6
		8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
		9. 7 and 8
Science Citation Index Expanded (http://portal.isi- knowledge.com/por- tal.cgi?DestAp- p=WOS&Func=Frame)	From 1900 to Octo- ber 2011.	#5 #4 AND #3
		#4 TS=(random* OR blind* OR placebo* OR meta-analysis)
		#3 #2 AND #1
		#2 TS=(leptospir*)
		#1 TS=(treat* OR therap*)

CONTRIBUTIONS OF AUTHORS

Conceiving the review: [pre-existing] Designing the review: DMB. Co-ordinating the review: DMB. Data collection for the review: DMB. Developing search strategy: DMB, RC, CHBG Staff. Undertaking searches: DMB, CHBG Staff. Screening search results: DMB, RC. Organising retrieval of papers: DMB. Screening retrieved papers against inclusion criteria: DMB, RC.

Appraising quality of papers: DMB, RC.

Abstracting data from papers: DMB, RC. Writing to authors of papers for additional information: DMB. Providing additional data about papers: DMB by responding authors. Obtaining and screening data on unpublished studies: for abstracts, DMB. Data management for the review: DMB. Entering data into RevMan: DMB. Analysis of data: DMB, RC. Interpretation of data: DMB, RC. Providing a methodological perspective: DMB, RC. Providing a clinical perspective: DMB, RC. Providing a policy perspective: DMB, RC. Providing a consumer perspective: DMB, RC. Providing a consumer perspective: DMB, RC. Providing a consumer perspective: DMB, RC. Providing a policy perspective: DMB, RC. Providing a consumer perspective: DMB, RC. Providing the review: DMB, RC.

Antibiotics for leptospirosis (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Securing funding for the review: NA. Performing previous work that was the foundation of current study: NA.

DECLARATIONS OF INTEREST

None known.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Multiple analyses for missing data were not indicated. Handling of three patient outcomes in a specific case is discussed (Risk of bias in included studies).

NOTES

This review replaces the review by Guidugli et al (Guidugli 2000).

Additional affiliations.

DMB - Program Director, U.S. Military Tropical Medicine, Navy Medicine Manpower Personnel Training and Education (NAVMED MPT&E), Bethesda MD; and, Assistant Professor, Divisions of Tropical Public Health and Infectious Diseases, Departments of Preventive Medicine and Biometrics, and Medicine, Uniformed Services University, Bethesda MD.

RC - Director, Division of Tropical Public Health, Department of Preventive Medicine and Biometrics, Uniformed Services University, Bethesda MD.

These views are those of the authors and do not necessarily reflect those of Navy Medicine Manpower, Personnel, Training & Education Command, Departments of the Army or Navy, Uniformed Services University, Department of Defense, or the U.S. Government.

INDEX TERMS

Medical Subject Headings (MeSH)

Anti-Bacterial Agents [*therapeutic use]; Cephalosporins [therapeutic use]; Doxycycline [therapeutic use]; Leptospirosis [*drug therapy] [mortality]; Penicillins [therapeutic use]; Randomized Controlled Trials as Topic

MeSH check words

Humans